文献速递产科母胎医学

小于胎龄儿预测与预防:来自SPREE与ASPRE研究的证据

Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-06-05

本研究基于两项多中心研究数据,分析孕早期子痫前期筛查对小于胎龄儿(SGA)的预测能力,以及阿司匹林预防SGA的效果。SPREE研究中联合筛查高危组涵盖约46%的早产SGA(<37周)和56%的早期SGA(<32周),筛查阳性率12.2%。ASPRE试验中阿司匹林使<37周SGA<第10百分位发生率降低约40%,<32周降低约70%,≥37周无显著效果。

要点

  • 孕早期联合筛查高危组涵盖约46%的早产SGA和56%的早期SGA。
  • 阿司匹林使<37周SGA<第10百分位发生率降低约40%,<32周降低约70%。
  • 阿司匹林对≥37周SGA发生率无显著影响。

核心结论

  • 孕早期联合筛查可识别大部分早产SGA病例,预防性使用阿司匹林可预防这些病例。

研究设计与样本

  • 数据来自两项多中心研究:SPREE研究分析孕11-13周联合筛查对子痫前期的筛查性能;ASPRE试验将联合筛查为早产子痫前期高风险(>1/100)的单胎孕妇随机分配至阿司匹林150 mg/天(孕11-14周至36周)或安慰剂组。
  • 本研究利用ASPRE试验数据估计阿司匹林对SGA(出生体重<第10、<第5、<第3百分位)发生率的影响,利用SPREE数据估计早产子痫前期风险>1/100孕妇中SGA的比例。

主要发现

  • SPREE研究中,联合筛查高危组涵盖约46%的<37周SGA<第10百分位和56%的<32周SGA,筛查阳性率12.2%(2014/16451)。
  • ASPRE试验中,阿司匹林使<37周SGA<第10百分位总体发生率降低约40%,<32周降低约70%;≥37周SGA发生率无显著影响。
  • 阿司匹林相关SGA发生率下降主要源于子痫前期孕妇中SGA发生率降低,<37周降低约70%,<32周降低约90%。
  • 基于上述结果估计,孕早期筛查早产子痫前期并在高危组使用阿司匹林可能使早产SGA和早期SGA发生率分别降低约20%和40%。

关键数值与推荐

  • 早产子痫前期高风险定义为联合筛查风险>1/100。
  • 阿司匹林用法为150 mg/天,从孕11-14周至36周。
  • SGA定义为出生体重<第10、<第5、<第3百分位。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the effect of first-trimester screening for pre-eclampsia (PE) on the prediction of delivering a small-for-gestational-age (SGA) neonate and the effect of prophylactic use of aspirin on the prevention of SGA. METHODS: The data for this study were derived from two multicenter studies. In SPREE, we investigated the performance of screening for PE by a combination of maternal characteristics and biomarkers at 11-13 weeks' gestation. In ASPRE, women with a singleton pregnancy identified by combined screening as being at high risk for preterm PE (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11-14 until 36 weeks' gestation) compared to placebo. In this study, we used the data from the ASPRE trial to estimate the effect of aspirin on the incidence of SGA with birth weight < 10th , < 5th and < 3rd percentile for gestational age. We also used the data from SPREE to estimate the proportion of SGA in the pregnancies with a risk for preterm PE of > 1 in 100. RESULTS: In SPREE, screening for preterm PE by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor identified a high-risk group that contained about 46% of SGA neonates < 10th percentile born at < 37 weeks' gestation (preterm) and 56% of those born at < 32 weeks (early); the overall screen-positive rate was 12.2% (2014 of 16 451 pregnancies). In the ASPRE trial, use of aspirin reduced the overall incidence of SGA < 10th percentile by about 40% in babies born at < 37 weeks' gestation and by about 70% in babies born at < 32 weeks; in babies born at ≥ 37 weeks, aspirin did not have a significant effect on incidence of SGA. The aspirin-related decrease in incidence of SGA was mainly due to its incidence decreasing in pregnancies with PE, for which the decrease was about 70% in babies born at < 37 weeks' gestation and about 90% in babies born at < 32 weeks. On the basis of these results, it was estimated that first-trimester screening for preterm PE and use of aspirin in the high-risk group would potentially reduce the incidence of preterm and early SGA by about 20% and 40%, respectively. CONCLUSION: First-trimester screening for PE by the combined test identifies a high proportion of cases of preterm SGA that can be prevented by the prophylactic use of aspirin. © 2018 Crown copyright. Ultrasound in Obstetrics & Gynecology © 2018 ISUOG.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Tan MY, Poon LC, Rolnik DL, et al. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018. PMID: 29704277. doi:10.1002/uog.19077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。